非伤寒沙门菌联合疫苗:临床开发计划与监管考量
在优选产品特征和研发路线图基础上,通过系列专家咨询形成了iNTS疫苗的临床开发计划和许可监管路径;多种iNTS单苗或与伤寒结合疫苗联合的平台正处于早期临床开发阶段,令人鼓舞的安全性和免疫原性数据促使开发者计划开展功效试验。
要点
- iNTS疾病从出生即可观察到,发病高峰在出生后第二年早期,3岁前下降。
- 多种iNTS单苗或与伤寒结合疫苗联合的平台正处于早期临床开发阶段。
核心结论
- iNTS疫苗的临床开发计划和监管许可路径已在优选产品特征和研发路线图基础上通过系列专家咨询形成。
- 多种iNTS单苗或与伤寒结合疫苗联合的平台正处于早期临床开发阶段,令人鼓舞的安全性和免疫原性数据促使开发者计划开展功效试验。
- 早期监管指导对于做出知情监管决策、指导临床开发计划和许可路径至关重要。
研究设计与样本
- 本文为临床开发计划与监管考量综述,基于优选产品特征和研发路线图通过系列专家咨询形成。
- 原文未报告系统检索范围。
主要发现
- 大多数感染发生在撒哈拉以南非洲低收入和中等收入国家的婴幼儿中,疟疾、营养不良、HIV感染和贫血等宿主危险因素常见。
- iNTS疾病从出生即可观察到,发病高峰在出生后第二年早期,3岁前下降。
- iNTS多重耐药患病率按十年显著增加。
关键数值与推荐
- 原文未报告具体推荐条款或阈值。
临床怎么用
- 需要清晰沟通iNTS疾病在地方性流行国家的疾病负担,并与监管机构讨论iNTS单组分或联合疫苗临床开发的复杂性。
- 小于6月龄婴儿的疾病负担是重要组成部分,将影响首次接种的最佳年龄(小于6月龄或6月龄起)、与国家扩大免疫规划程序的兼容性以及是否需要加强剂次。
- 持续与公共卫生利益相关方和最终用户代表沟通将有效促进对iNTS疾病及疫苗接种所提供保护的认知和教育。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Invasive non-typhoidal serovars of Salmonella enterica,S. Typhimurium and S. Enteritidis, (iNTS) are estimated to cause over 500,000 cases of disease leading to more than 79,000 deaths with a high case fatality ratio of 14.5 %. Most infections occur in infants and young children in LMICs in sub-Saharan Africa where host risk factors for iNTS disease such as malaria, malnutrition, HIV infection, and anemia are common. iNTS disease is observed from birth, with a peak incidence early in the second year of life, declining before the age of 3 years. The prevalence of multiple drug resistance of iNTS has increased markedly by decade, emphasizing the need for effective vaccines. A clinical development plan and regulatory pathway for licensure of iNTS vaccines has been shaped following the development of Preferred Product Characteristics and R&D Roadmap through a series of expert consultations. Several iNTS alone or combined with Typhoid Conjugate Vaccine platforms are in early clinical development. Encouraging safety and immunogenicity data have prompted developers and manufacturers to plan efficacy trials, aligned with regulatory expectations. It is critical to clearly communicate iNTS disease burden in endemic countries and to discuss complexities related to iNTS single component or combination vaccine clinical development with regulators. An essential component is the disease burden in infants less than 6 months of age, which will inform the optimal age of first vaccination (less than or from 6 months), compatibility across national expanded programme on immunization schedules, and whether a booster dose would be needed. Early regulatory guidance is essential to make informed regulatory decisions and to guide the clinical development plan and licensure pathway. Continued communication with public health stakeholders and end-user representatives will effectively contribute to better awareness and education about iNTS disease and protection afforded by vaccination.
引用
- Excler JL, Saluja T, Wilder-Smith A, et al. Non-typhoidal Salmonella combination vaccines: clinical development plan and regulatory considerations. Vaccine. 2025. PMID: 40684736. doi:10.1016/j.vaccine.2025.127515
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。